SCHEMBL7986975

SCHEMBL7986975

CCS(=O)(=O)NC(=O)c1cccc(OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.59
RAB9A P51151 6/20 0.59
TAS1R3 Q7RTX0 1/20 0.58
TAS1R1 Q7RTX1 1/20 0.58
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 2/20 0.56
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
KAT6A Q92794 1/20 0.56
TSHR P16473 2/20 0.55
NPSR1 Q6W5P4 1/20 0.55
RXFP1 Q9HBX9 1/20 0.54
KCNK3 O14649 1/20 0.54
KCNK9 Q9NPC2 1/20 0.54
KDM4E B2RXH2 1/20 0.54
TP53 P04637 1/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7973370 0.90 TAS1R3 (0.58) NPC1RAB9ATAS1R3TAS1R1MEN1
SCHEMBL7984969 0.87 KAT6A (0.61) NPC1RAB9AKMT2ASMN1; SMN2KAT6A
SCHEMBL2172190 0.84 NPC1 (0.62) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL7984993 0.83 SMPD1 (0.67) MEN1KMT2AKAT6A
SCHEMBL7983736 0.81 CA1 (0.62) NPC1RAB9ATAS1R3TAS1R1KMT2A
SCHEMBL1012519 0.80 NPC1 (0.70) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL47353 0.80 MMP13 (0.66) NPC1RAB9ATAS1R3TAS1R1MEN1
SCHEMBL7984974 0.80 L3MBTL1 (0.59) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL7984819 0.80 HDAC8 (0.64) NPC1RAB9ATAS1R3TAS1R1MEN1
SCHEMBL29598340 0.79 NPC1 (0.68) NPC1RAB9ATAS1R3TAS1R1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663508-B2 Biaryl acyl-sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-05-30 US disclosed
US-20160214971-A1 Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors One Amgen Center Drive (US) 2016-07-28 US disclosed
WO-2015051043-A1 BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2015-04-09 WO disclosed
US-6331628-B1 REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214971-A1 Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors SCN1A, SCN1B, SCN5A NPC1 698/4885RAB9A 1288/4885TAS1R3 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.